|Institutional Source||Beutler Lab|
|Gene Name||squamous cell carcinoma antigen recognized by T cells 1|
|Is this an essential gene?||Essential (E-score: 1.000)|
|Stock #||R0226 (G1)|
|Chromosomal Location||5377523-5388703 bp(-) (GRCm38)|
|Type of Mutation||splice site|
|DNA Base Change (assembly)||C to T at 5381122 bp (GRCm38)|
|Amino Acid Change|
|Ref Sequence||ENSEMBL: ENSMUSP00000047397 (fasta)|
|Gene Model||predicted gene model for transcript(s): [ENSMUST00000044207]|
|Meta Mutation Damage Score||0.0898|
|Coding Region Coverage||
|Validation Efficiency||100% (98/98)|
|MGI Phenotype||FUNCTION: [Summary is not available for the mouse gene. This summary is for the human ortholog.] This gene encodes two proteins, the SART1(800) protein expressed in the nucleus of the majority of proliferating cells, and the SART1(259) protein expressed in the cytosol of epithelial cancers. The SART1(259) protein is translated by the mechanism of -1 frameshifting during posttranscriptional regulation; its full-length sequence is not published yet. The two encoded proteins are thought to be involved in the regulation of proliferation. Both proteins have tumor-rejection antigens. The SART1(259) protein possesses tumor epitopes capable of inducing HLA-A2402-restricted cytotoxic T lymphocytes in cancer patients. This SART1(259) antigen may be useful in specific immunotherapy for cancer patients and may serve as a paradigmatic tool for the diagnosis and treatment of patients with atopy. The SART1(259) protein is found to be essential for the recruitment of the tri-snRNP to the pre-spliceosome in the spliceosome assembly pathway. [provided by RefSeq, Jul 2008]|
|Allele List at MGI|
|Other mutations in this stock||
|Other mutations in Sart1||
(F):5'- TGGCAGTCAGCACAGGTGTAAC -3'
(R):5'- CTGCTGGAGACCACAGTACAAAAGG -3'
(F):5'- TGGGAACTTCAGTACTACGC -3'
(R):5'- ACAGTACAAAAGGTGGCCC -3'